Identification
- Generic Name
- Alunacedase alfa
- DrugBank Accession Number
- DB15736
- Background
Alunacedase alfa is a recombinant and soluble glycosylated form of human ACE2. This recombinant version of the enzyme has antihypertensive and potential antineoplastic activities.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Recombinant Enzymes - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Alunacedase alfa
- Recombinant Human Angiotensin-Converting Enzyme 2
- rhACE2
- External IDs
- APN-01
- APN01
- GSK-2586881
- GSK2586881
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Angiotensin Converting Enzyme 2 (ACE2) degrades Angiotensin II (known as Ang1-8) into Ang1-7. Angiotensin II exerts actions like inflammation, ROS production, and vasoconstriction, and is implicated in acute respiratory distress syndrome (ARDS). Its conversion to Ang1-7 by ACE2 contrasts these actions as Ang1-7 promotes vasodilation, anti-inflammation, and NO release -- attenuating tissue injury which includes ARDS-associated injury. Additional administration of ACE2 by way of a recombinant protein is thought to aid in conversion of excessive Ang1-8 associated with ARDS into Ang1-7, and help reduce the damaging effects of the renin-angiotensin system. This compound, as such, is being investigated for lung injury and ARDS associated with COVID-19.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- FA2I4Z873U
- CAS number
- 2416824-55-8
References
- General References
- Khan A, Benthin C, Zeno B, Albertson TE, Boyd J, Christie JD, Hall R, Poirier G, Ronco JJ, Tidswell M, Hardes K, Powley WM, Wright TJ, Siederer SK, Fairman DA, Lipson DA, Bayliffe AI, Lazaar AL: A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care. 2017 Sep 7;21(1):234. doi: 10.1186/s13054-017-1823-x. [Article]
- Haschke M, Schuster M, Poglitsch M, Loibner H, Salzberg M, Bruggisser M, Penninger J, Krahenbuhl S: Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin Pharmacokinet. 2013 Sep;52(9):783-92. doi: 10.1007/s40262-013-0072-7. [Article]
- NCBI MedGen: Recombinant Human Angiotensin Converting Enzyme 2 APN01 [Link]
- Phase 2 Clinical Trial of APN01 for Treatment of COVID-19 Inititated [Link]
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Coronavirus Disease 2019 (COVID‑19) 1 2 Completed Treatment Lung Injury, Acute (ALI) 1 2 Completed Treatment Pulmonary Hypertension (PH) 1 1 Completed Treatment Cancer Diseases / Cardiovascular Disease (CVD) / Kidney Diseases / Lung Disorder 1 1 Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) 1 1 Terminated Treatment Healthy Subjects (HS) 1 Not Available Withdrawn Treatment Coronavirus Disease 2019 (COVID‑19) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at August 11, 2020 20:25 / Updated at February 21, 2021 18:55